Back to top

crispr: Archive

Zacks Equity Research

Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up

Editas (EDIT) reports better-than-expected fourth-quarter 2023 results as both earnings and revenues beat estimates, driven by collaboration revenues received from Vertex. The stock gains 25%.

VRTXNegative Net Change ACETNegative Net Change EDITPositive Net Change AKRONegative Net Change

Zacks Equity Research

CRISPR (CRSP) Q4 Earnings Top on Collaboration Revenues, Stock Up

CRISPR (CRSP) gains on encouraging fourth-quarter 2023 results, beating both earnings and revenue estimates on the back of collaboration revenues received from Vertex.

VRTXNegative Net Change PBYIPositive Net Change ADMANegative Net Change CRSPNegative Net Change